Veness Adam M 4
4 · ACCELERON PHARMA INC · Filed Sep 22, 2021
Insider Transaction Report
Form 4
Veness Adam M
VP, General Counsel and Sec.
Transactions
- Exercise/Conversion
Common Stock
2021-09-21$41.20/sh+1,450$59,740→ 25,573 total - Exercise/Conversion
Option to Purchase Common Stock
2021-09-21−1,450→ 0 totalExercise: $41.20Exp: 2025-01-08→ Common Stock (1,450 underlying) - Exercise/Conversion
Common Stock
2021-09-21$30.17/sh+5,200$156,884→ 24,123 total - Exercise/Conversion
Option to Purchase Common Stock
2021-09-21−5,200→ 0 totalExercise: $30.17Exp: 2027-03-02→ Common Stock (5,200 underlying) - Sale
Common Stock
2021-09-21$150.05/sh−6,650$997,833→ 18,923 total
Footnotes (4)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017.
- [F4]The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2015.